DENOSUMAB:

A NEW TREATMENT OPTION FOR OSTEOPOROSIS

Abstract

Osteoporosis is the most common metabolic bone disease in developed countries. One of its major problems is the long term
morbidity and poor quality of life of patients. Receptor activator of nuclear factor-kB, its ligand and osteoprotegrin pathway plays an important
role in bone remodeling. Receptor activator of nuclear factor-kB interacts with receptor activator of nuclear factor-kB ligand leading to activation
of osteoclasts. Denosumab, a fully monoclonal antibody to receptor activator of nuclear factor-kB ligand prevents its binding to receptor
activator of nuclear factor-kB and can effectively suppress the bone loss in osteoporosis. Various clinical studies have shown that Denosumab
has good efficacy in decreasing bone resorption and has a favourable safety profile also.